Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Coegin Pharma

4.36 SEK

+1.87 %

Less than 1K followers

COEGIN

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+1.87 %
-1.80 %
-12.45 %
-34.73 %
+27.49 %
+3.32 %
-62.25 %
-75.19 %
-86.29 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Read more
Market cap
108.47M SEK
Turnover
15.57K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

21/5
2026

Interim report Q1'26

21/5
2026

General meeting '26

All
Press releases
ShowingAll content types
Press release1/2/2026, 8:30 AM

Coegin Pharma provides an operational and strategic update

Coegin Pharma
Press release12/22/2025, 12:30 PM

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Coegin Pharma
Press release12/19/2025, 8:25 AM

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Coegin Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release12/12/2025, 10:50 AM

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Coegin Pharma
Regulatory press release11/27/2025, 8:45 AM

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Coegin Pharma
Regulatory press release11/20/2025, 1:50 PM

Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025

Coegin Pharma
Press release11/14/2025, 1:42 PM

First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma

Coegin Pharma
Press release11/6/2025, 1:45 PM

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Coegin Pharma
Regulatory press release10/17/2025, 3:05 PM

Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand

Coegin Pharma
Press release10/13/2025, 8:02 AM

Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth

Coegin Pharma
Regulatory press release9/17/2025, 12:30 PM

Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland

Coegin Pharma
Regulatory press release9/10/2025, 1:00 PM

Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation

Coegin Pharma
Regulatory press release8/21/2025, 12:30 PM

Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025

Coegin Pharma
Press release8/20/2025, 6:30 AM

Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product

Coegin Pharma
Regulatory press release8/12/2025, 12:45 PM

Coegin Pharma changes language for company communication to English

Coegin Pharma
Regulatory press release8/12/2025, 12:45 PM

Coegin Pharma ändrar språk för informationsgivning till engelska

Coegin Pharma
Press release7/2/2025, 6:30 AM

Coegin Pharma has reduced product cost by 80 percent - moving closer to the launch of Follicopeptide

Coegin Pharma
Press release7/2/2025, 6:30 AM

Coegin Pharma har sänkt produktkostnaden med 80 procent - närmar sig lansering av Follicopeptide

Coegin Pharma
Regulatory press release5/22/2025, 11:30 AM

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release5/22/2025, 11:30 AM

Kommuniké från årsstämma i Coegin Pharma AB (publ)

Coegin Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.